YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

Rhea-AI Summary

YD Bio (Nasdaq: YDES) rang the Nasdaq Opening Bell on October 20, 2025 to mark its listing on the Nasdaq Global Market. The company said the listing strengthens its capital base, elevates its global profile and accelerates commercialization of DNA methylation cancer-detection tests and exosome-based ophthalmologic therapies.

YD Bio highlighted exclusive 20-year licenses from EG Biomed and 3D Global Biotech, plans to expand R&D and a Seattle-based CLIA and CAP certified laboratory, and indicated the listing will support product launches and long-term value for patients and investors.

Positive

• Nasdaq listing completed on October 20, 2025, increasing U.S. market access
• Exclusive 20-year licenses from EG Biomed and 3D Global Biotech
• Seattle CLIA and CAP certified lab to support commercialization and testing

Negative

• None.

Taipei, Taiwan, Oct. 20, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today rang the Opening Bell at Nasdaq MarketSite in New York to celebrate its public listing on the Nasdaq Global Market. This milestone strengthens YD Bio’s capital base, elevates its global profile and accelerates the commercialization of its next-generation diagnostic and regenerative medicine platforms.

“Our Nasdaq listing is a testament to the dedication of our team and the strength of our strategic partnerships,” said Dr. Ethan Shen, Chairman and CEO of the Company. “With exclusive 20-year licenses from EG Biomed and 3D Global Biotech, we’re poised to scale our non-invasive cfDNA methylation tests for early cancer detection and our exosome-based eye therapies worldwide. This expanded access to U.S. capital markets will turbocharge R&D, grow our Seattle-based CLIA and CAP certified laboratory and fuel the launch of our pipeline products, driving long-term value for patients and investors.”

Since its founding in 2013, YD Bio has evolved from a clinical trial drug supplier into a diversified biotech innovator. The Company's strategic alliances, leveraging EG BioMed Co., Ltd.'s expertise in DNA methylation and 3D Global Biotech Inc.'s regenerative-medicine platforms, provide a significant competitive advantage and support a promising pipeline targeting multi-billion-dollar markets in which YD Bio operates.

About YD Bio Limited
YD Bio Limited is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, stem cell and exosome therapies with the potential to transform the treatment of diseases with high unmet medical need. The Company is committed to improving patient outcomes through scientific innovation and precision medicine. In addition to its R&D efforts, YD Bio Limited is a recognized supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. For more information, please visit the Company’s website: ir.ydesgroup.com

Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, including, but not limited to, YD Bio’s business plan and outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on YD Bio’s current expectations and projections about future events that YD Bio believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. YD Bio undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although YD Bio believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and YD Bio cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in YD Bio’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:
YD Bio Limited
Investor Relations
Email: investor@ydesgroup.com

FAQ

When did YD Bio (YDES) list on Nasdaq and what does the listing mean?

YD Bio listed on the Nasdaq Global Market on October 20, 2025; the company said the listing strengthens its capital base and global profile to accelerate commercialization.

What intellectual property does YD Bio (YDES) hold for its cancer and eye therapies?

YD Bio holds exclusive 20-year licenses from EG Biomed and 3D Global Biotech for DNA methylation tests and regenerative-medicine platforms.

How will YD Bio (YDES) use U.S. capital market access after the Nasdaq listing?

The company plans to use expanded U.S. capital access to turbocharge R&D, grow its Seattle lab and fund pipeline product launches.

Does YD Bio (YDES) have a certified laboratory to support diagnostics?

Yes; YD Bio stated it has a Seattle-based CLIA and CAP certified laboratory to support commercialization of its tests.

What technologies is YD Bio (YDES) advancing after the Nasdaq listing?

YD Bio is advancing cfDNA methylation-based non-invasive cancer detection and exosome-based ophthalmologic therapies.